 Also, a death occurred possibly due to epidermal growth factor receptor tyrosine kinase inhibitor treatment; however, the correlation is not exactly clear.In addition, skin toxicity was observed in 62% of patients in the 250 mg group.Nevertheless, the side-effects of Gefitinib were only “generally mild, manageable, noncumulative, and reversible.” Unfortunately, ceasing to take the inhibitor may be the only reversal strategy of the unfavorable symptoms.